NCT06080776 2023-10-12SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR MutationsNanjing Sanhome Pharmaceutical, Co., Ltd.Phase 3 Recruiting242 enrolled